Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin.
Cell-of-Origin Subtypes and Therapeutic Benefit from Polatuzumab Vedotin.
复制标题
Polatuzumab Vedotin 的起源细胞亚型和治疗益处。
DOI：
10.1056/nejmc2306105
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Alizadeh,AshA
中科院分区：
文献类型：
--
作者：
Palmer,AdamC;Kurtz,DavidM;Alizadeh,AshA
大B细胞淋巴瘤的起源细胞和治疗对Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的既往试验的分析表明，该药物对一种亚型（活化B细胞）的肿瘤比另一种亚型（生殖中心B细胞）的肿瘤更有效。
Cell of Origin and Therapy for Large B-Cell LymphomaAnalysis of previous trials of polatuzumab vedotin for diffuse large B-cell lymphoma showed that the drug was more effective for tumors of one subtype (activated B cell) than those of another subtype (germinal-center B cell).